Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer
pharmafile | February 10, 2026 | Appointment | | Angelini Pharma
Angelini Pharma, the pharmaceutical branch of Angelini Industries, has announced the appointment of Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer.
Scrivo brings more than 25 years of public and private sector experience to his new role at Angelini Pharma. He was previously Chief of Public Affairs and Corporate Communications and Sustainability Officer at the Engineering Group, as well as being a member of the Group’s leadership team. Other former roles include Public Affairs Senior Director at Sky Italia, Head of Public Affairs at Fastweb and senior roles in the Italian Ministry of Health.
Scrivo has worked across sectors including healthcare, media and technology, and his areas of expertise include institutional relations, stakeholder engagement and reputation management.
In his new role, Scrivo will assist in leading Angelini Pharma’s global initiatives in corporate relations, communications and sustainability. He will report to Angelini Pharma CEO Sergio Marullo di Condojanni.
di Condojanni said: “Roberto’s extensive experience and clear strategic vision will provide a significant contribution to supporting Angelini Pharma’s growth and sustainable positioning.”
Scrivo added: “[Angelini Pharma] is a trusted partner to healthcare institutions and patients, thanks to its century-long legacy, strong social commitment, continuous investment in innovation and the reliability of its products”.
Angelini Pharma is a pharmaceutical company specialising in a number of key therapeutic areas, including brain health (encompassing both neurology and psychiatry), specialty and primary care, and consumer health.
Related Content
Angelini Pharma and JCR Pharmaceuticals partner to develop new epilepsy therapies
Angelini Pharma and JCR Pharmaceuticals have announced that they have entered into an exclusive global …
Angelini Pharma to acquire Arvelle Therapeutics in $960 million deal
Angelini Pharma is set to acquire Arvelle Therapeutics, a biopharmaceutical company focused on bringing innovative …
